Synthesis and structure - Activity relationship of α-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis

Journal of Medicinal Chemistry

Volumn 46, Issue 12, 2003, Pages 2361-2375

  Aranapakam, Venkatesan ^a   Grosu, George T ^a   Davis, Jamie M ^a   Hu, Baihua ^a   Ellingboe, John ^a   Baker, Jannie L ^a   Skotnicki, Jerauld S ^a   Zask, Arie ^a   DiJoseph, John F ^b   Sung, Amy ^b   Sharr, Michele A ^b   Killar, Loran M ^b   Walter, Thomas ^b   Jin, Guixian ^a   Cowling, Rebecca ^a  

^a WYETH RESEARCH   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 AZEPAN 1 YLETHOXY)BENZYL] 2 (4 METHOXYBENZENESULFONYL)PROPIONIC ACID HYDROXYAMIDE; COLLAGENASE 3; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE INHIBITOR; N HYDROXY 2 (4 METHOXYBENZENESULFONYL) 2 METHYL 3 [4 (2 PIPERIDIN 1 YLETHOXY)PHENYL]PROPIONAMIDE; N HYDROXY 2 (4 N BUTOXYBENZENESULFONYL) 2 METHYL 3 [4 (2 PIPERIDIN 1 YLETHOXY)PHENYL]PROPIONAMIDE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTHRITIS; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME REGULATION; GENE OVEREXPRESSION; IC 50; IN VITRO STUDY; INHIBITION KINETICS; METASTASIS; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOARTHRITIS; REGULATORY MECHANISM; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADAM PROTEINS; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL ASSAY; CARTILAGE; CATTLE; COLLAGENASES; DIALYSIS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; METALLOENDOPEPTIDASES; MICE; OSTEOARTHRITIS; PROTEASE INHIBITORS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 12444335919     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0205548     Document Type: Article

References (25)

1. Johnson, L. L.; Dyer, R.; Hupe, D. J. Matrix Metalloproteinases. Curr. Opin. Chem. Biol. 1998, 2, 466.
2. Shapiro, S. D. Matrix metalloproteinase degradation of extra-cellular matrix: biological consequences. Curr. Opin. Cell Biol. 1998, 10, 602.
3. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, J. H. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 1999, 99, 2735.
4. Nagase, H.; Woessner, J. F., Jr. Matrix metalloproteinases. J. Biol. Chem. 1999, 274, 21419.
5. Ray, J. M.; Stetler-Stevenson, W. G. The role of matrix metalloproteases and their inhibitors in tumor invasion, metastasis and angiogenesis. Eur. Respir. J. 1994, 7 (11), 2062.
6. George, S. J. Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. Curr. Opin. Lipidol. 1998, 9, 413.
7. Haas, T. L.; Madri, J. A. Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc. Med. 1999, 9, 70.
8. Thomas, G. T.; Lewis, M. P.; Speight, P. M. Matrix metalloproteinases and oral cancer. Oral Oncol. 1999, 35, 227.
9. Mousa, S. A. Mechanism of angiogenesis in vascular disorders: potential therapeutic targets. Drugs Future 1998, 23, 51.
10. Westermarck, J.; Kahari, V. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999, 13, 781.
11. Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem. 2001, 8, 425.
12. Moss, M. L.; White, J. M.; Lambert, M. H.; Andrews, R. C. TACE and other ADAM proteases as targets for drug discovery. Drug Discovery Today 2001, 6, 417.
13. Raveendranath, P.; Zeldis, J.; Vid, G.; Potoski, J. R.; Ren, J. Preparation of N-[(aryloxy)alkyl]piperidines and analogs as pharmaceutical intermediates. Patent WO 9919293 A1, 1999.
14. (a) Weingarten, H.; Feder, J. Spectrophotometric assay for vertebrate collagenase. Anal. Biochem. 1985, 147, 437.
15. 50 values determinations were calculated from a four-parameter logistic fit of the data within a single experiment. The final values given here are the mean of the triplicate values of the sample.
16. Jin, G.; Black, R.; Wolfson, M.; Rauch, C.; McGregor, H.; Ellestad, G. A.; Cowling, R. A. Continuous Fluorimetric Assay for Tumor Necrosis Factor-α Converting Enzyme. Anal. Biochem. 2002, 302, 269.
17. (a) Yip, D.; Ahmad, A.; Karapetis, C. S.; Hawkins, C. A.; Harper, P. G. Matrix metalloproteinase inhibitors: applications in oncology. Invest. New Drugs 1999, 17, 387-399.
18. (b) Nelson, A. R.; Fingleton, B.; Rothenberg, M. L.; Matrisian, L. M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 2000, 18, 1135.
19. Levin, J. I.; Du, M. T.; DiJoseph, J. F.; Killar, L. M.; Sung, A.; Walter, T.; Sharr, M. A.; Roth, C. E.; Moy, F. J.; Powers, R.; Jin, G.; Cowling, R.; Skotnicki, J. S. The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. Bioorg. Med. Chem. Lett. 2001, 11, 235.
20. Newton, R. C.; Decicco, C. P. Therapeutic potential and strategies for inhibiting tumor necrosis factor-α. J. Med. Chem. 1999, 42, 2295.
21. Scrip 1998, 2349, 20-21.
22. DiJoseph, J. F.; Sharr, M. A. Dialysis Tubing Implant Assay in the Rat - A Novel in Vivo Method for Identifying Inhibitors of Matrix Metalloproteinases. Drug Dev. Res. 1998, 43, 200.
23. Bishop, J.; Greenham, A. K.; Lewis, E. J. A novel in vivo model for the study of cartilage degradation. J. Pharmacol. Toxicol. Methods 1993, 30, 19.
24. (a) Moy, F. J.; Chanda, P. K.; Chen, J. M.; Cosmi, S.; Edris, W.; Levin, J. I.; Powers, R. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor. J. Mol. Biol. 2000, 302, 671.
25. 13CO assignments and secondary structure determination of collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor. J. Biomol. NMR 2000, 17, 269.